AU673212B2 - Determination of peptide motifs on MHC molecules - Google Patents

Determination of peptide motifs on MHC molecules

Info

Publication number
AU673212B2
AU673212B2 AU54656/94A AU5465694A AU673212B2 AU 673212 B2 AU673212 B2 AU 673212B2 AU 54656/94 A AU54656/94 A AU 54656/94A AU 5465694 A AU5465694 A AU 5465694A AU 673212 B2 AU673212 B2 AU 673212B2
Authority
AU
Australia
Prior art keywords
peptide motifs
determination
mhc molecules
disclosed
mhc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU54656/94A
Other versions
AU5465694A (en
Inventor
Kirsten Falk
Gunther Jung
Hans-Georg Rammensee
Olaf Rotzschke
Stefan Stevanovic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Original Assignee
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft zur Foerderung der Wissenschaften eV filed Critical Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Publication of AU5465694A publication Critical patent/AU5465694A/en
Application granted granted Critical
Publication of AU673212B2 publication Critical patent/AU673212B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A process is disclosed for determining allele-specific peptide motifs on molecules of the major histocompatibility complex (MHC) of classes (I) and (II), as well as the peptide motifs obtained by this process. Also disclosed is the used of said peptide motifs for preparing a diagnostic or therapeutical agent.
AU54656/94A 1992-11-13 1993-11-12 Determination of peptide motifs on MHC molecules Ceased AU673212B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE4238416A DE4238416A1 (en) 1992-11-13 1992-11-13 Determination of peptide motifs on MHC molecules
DE4238416 1992-11-13
PCT/EP1993/003175 WO1994011738A1 (en) 1992-11-13 1993-11-12 Determination of peptide motifs on mhc molecules

Publications (2)

Publication Number Publication Date
AU5465694A AU5465694A (en) 1994-06-08
AU673212B2 true AU673212B2 (en) 1996-10-31

Family

ID=6472850

Family Applications (1)

Application Number Title Priority Date Filing Date
AU54656/94A Ceased AU673212B2 (en) 1992-11-13 1993-11-12 Determination of peptide motifs on MHC molecules

Country Status (11)

Country Link
EP (1) EP0669001B1 (en)
JP (1) JPH07509319A (en)
KR (1) KR100194117B1 (en)
AT (1) ATE158082T1 (en)
AU (1) AU673212B2 (en)
CA (1) CA2147863C (en)
DE (2) DE4238416A1 (en)
DK (1) DK0669001T3 (en)
ES (1) ES2109658T3 (en)
GR (1) GR3025655T3 (en)
WO (1) WO1994011738A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7611713B2 (en) 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
US7252829B1 (en) 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
US9340577B2 (en) 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
AU6359494A (en) * 1993-03-05 1994-09-26 Epimmune, Inc. Hla-a2.1 binding peptides and their uses
US5610013A (en) * 1993-07-22 1997-03-11 Ludwig Institute For Cancer Research Method for diagnosing a disorder by determining expression of gage tumor rejection antigen precursors
US5648226A (en) * 1993-07-22 1997-07-15 Ludwig Institute For Cancer Research Isolated peptides derived from tumor rejection antigens, and their use
US7025964B1 (en) 1996-11-13 2006-04-11 Meiji Dairies Corporation Peptide-based immunotherapeutic agent
WO1998022141A2 (en) * 1996-11-19 1998-05-28 Sangstat Medical Corporation Enhanced effects for hapten conjugated therapeutics
US6413517B1 (en) 1997-01-23 2002-07-02 Epimmune, Inc. Identification of broadly reactive DR restricted epitopes
US6977074B2 (en) 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US6994851B1 (en) 1997-07-10 2006-02-07 Mannkind Corporation Method of inducing a CTL response
EP1230268B1 (en) 1999-11-18 2009-10-14 Pharmexa Inc. Heteroclitic analogs of class i epitopes
US7026443B1 (en) 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
US7462354B2 (en) 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
NZ521898A (en) 2000-03-31 2004-11-26 Purdue Research Foundation Use of a ligand-immunogen conjugate such as folate-FITC for enhancing an endogenous immune response
US6861234B1 (en) 2000-04-28 2005-03-01 Mannkind Corporation Method of epitope discovery
DK1453471T3 (en) 2001-11-07 2011-03-28 Mannkind Corp Expression vectors encoding epitopes of antigens and method of their construction
US20040072262A1 (en) 2002-10-11 2004-04-15 Montero-Julian Felix A. Methods and systems for detecting MHC class I binding peptides
EP2226332A1 (en) 2004-06-17 2010-09-08 Beckman Coulter, Inc. Mycobacterium tuberculosis epitopes and methods of use thereof
JP5792630B2 (en) 2009-01-28 2015-10-14 エピミューン，インコーポレイティド PAN-DR binding polypeptides and uses thereof
EP3054010B1 (en) * 2013-10-03 2020-07-22 Sapporo Medical University Tumor antigen peptide
US20210215707A1 (en) * 2018-08-14 2021-07-15 Board Of Regents, The University Of Texas System Single molecule sequencing peptides bound to the major histocompatibility complex

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU619458B2 (en) * 1987-01-30 1992-01-30 Board Of Trustees Of The Leland Stanford Junior University Lymphocyte inhibition by hla peptides
DE4143467C2 (en) * 1991-05-17 1995-02-09 Max Planck Gesellschaft Peptide motif and its use

Also Published As

Publication number Publication date
EP0669001A1 (en) 1995-08-30
CA2147863C (en) 2002-12-24
CA2147863A1 (en) 1994-05-26
DK0669001T3 (en) 1998-05-04
EP0669001B1 (en) 1997-09-10
WO1994011738A1 (en) 1994-05-26
AU5465694A (en) 1994-06-08
KR950704688A (en) 1995-11-20
ATE158082T1 (en) 1997-09-15
DE59307354D1 (en) 1997-10-16
DE4238416A1 (en) 1994-05-19
KR100194117B1 (en) 1999-06-15
JPH07509319A (en) 1995-10-12
GR3025655T3 (en) 1998-03-31
ES2109658T3 (en) 1998-01-16

Similar Documents

Publication Publication Date Title
AU673212B2 (en) Determination of peptide motifs on MHC molecules
CA2103148A1 (en) Determination of motifs of peptides on mhc molecules
AU4725796A (en) Preparation and use of a specific gaba-A alpha 5 receptor ligand for treatment of Alzheimer's disease
NO993247D0 (en) Process for the preparation of tolterodine
AU6613896A (en) Chemical compounds
HUT54119A (en) Process for producing antiinflammatory aminophenol derivatives
AU1436097A (en) Sulphamate derivatives of 1,3,5(10)-estratriene derivatives, methods of producing them and pharmaceutical compounds containing them
GB9126725D0 (en) Process
AU6489190A (en) Synthesis of polydiene rubber by high solids solution polymerization
AU6393686A (en) Process for preparing halogen magnesium alanate and use thereof
AU7429087A (en) New androst-4-ene-3,17-diones and process for their preparation
MY129947A (en) Novel substituted thienopyrans as antihypertensive agents.
IL65597A (en) Preparation of 1alpha,24,25-trihydroxy-and 24,25-dihydroxy-cholesterol and certain novel intermediates used therein
UA35556C2 (en) process for the preparation of hydrocortisone AND INTERMEDIATE compounds in the synthesis of hydrocortisone
TW326033B (en) Cyanobenzenesulfenyl halide and process for preparation of 3-substituted benzisothiazole using the same
AU629395B2 (en) Device for the wet-treatment of hides
AU1966888A (en) Process for stabilizing mixtures based on halogenated polymers
GR1001203B (en) Method for the preparation of the compound 24r-scymnol
HU913573D0 (en) Complexes containing s(+)alkaneacids and alpha-hydroxy-alkaneacids
ID28174A (en) TURUNAN 5-IMINO-13-DEOKSI ANTRASIKLIN, IT IS USED, AND THE PROCESS IS
AU6290398A (en) Inclusion complexes in aqueous solution
FR2708928A1 (en) Process for the preparation of dialkyl 2-halo-ethyl-malonates.
ES2149269T3 (en) PROCEDURE FOR THE PREPARATION OF BETA-LACTAMS.
ES2100787A1 (en) Process for the preparation of various compounds derived from hexachlorocyclotriphosphazene
AU1568995A (en) Analogs of thymosin alpha1